口罩EUA申请美国出口认证办理

口罩EUA申请办理，口罩产品出口美国地区EUA申请，未在美国境内的上市的医疗用途的外科口罩、N95口罩，不管是美国境内还是境外制造商，都可以申请紧急授权。需要递交以下资料，并发送到FDA 这个邮gicalMasks@fda.hhs.gov，由FDA审核是否可以授予紧急授权，让该产品在新冠疫情期间在美国境内销售。

未在美国境内的上市的医疗用途的外科口罩、N95口罩，不管是美国境内还是境外制造商，都可以申请紧急授权。需要递交以下资料，并发送到FDA 这个邮gicalMasks@fda.hhs.gov，由FDA审核是否可以授予紧急授权，让该产品在新冠疫情期间在美国境内销售。

资料如下：

1、General information such as your contact information, name and place of business,email address, and contact information for a U.S. agent (if any) in addition to generalinformation about the device such as the proprietary or brand name, model number,and marketing authorization in your country (or region).

2、copy of the product labeling.

3、Whether the device currently has marketing authorization in another regulatory jurisdiction (including certification number, if available).

4、Whether the device is manufactured in compliance with 21 CFR Part 820 or ISO13485: Medical Devices – Management Systems – Re forRegulatory Purposes or an e system and the manufacturer or importer has documentation of such.

5、Description of testing conducted on the device, including any standards met, such as

6、liquid barrier protection, flammability, biocompatibility, and filtration performance, asappropriate. For surgical N95 respirators, FDA recommends including fluid resistance testing (liquid barrier performance).

以上递交资料适用于本来就已经生产医疗器械、但口罩尚未在美国境内上市的制造商。有两点是需要注意的：

1、FDA只是减免了510（k）技术文档要求，但关于产品测试，生产车间质量体系的要求是从未有放弃的；

2、在新冠肺炎疫情爆发期间内，FDA不拘泥于任何区域的产品标准，只要你是做相关产品测试，欧盟的、中国的，都可以将测试报告递交，由FDA决定是否可以授予紧急授权。

此外，FDA也欢迎非医疗器械企业生产销售医疗器械，可以粗暴理解成就是连生产车间QSR820都未外审过的制造商，至于要怎么操作，发邮件问FDA。

额外要求

FDA对于紧急授权下的口罩产品，有如下要求：

Appropriate conditions designed to ensure that health care professionals administering the device are informed—

that FDA has authorized the emergency use of the device;

of the significant known and potential benefits and risks of the emergency use of the device, and of the extent to which such benefit and risks are unknown;

of the alternatives to the device that are available, and of their benefits and risks.

Appropriate conditions designed to ensure that individuals to whom the device is administered are informed—

that FDA has authorized the emergency

of the option to accept or refuse administration of the device, of the consequence,if any, of refusing administration of the device, and of the alternatives to the device that are available and of their benefits and risks.